BridgeMD
New treatment option for ST-segment Elevation Myocardial Infarction (STEMI)
Official title Thrombus Aspiration in STEMI Patients With High Thrombus Burden
ClinicalTrials.gov ID: NCT04212494
What this study is testing
- What it's testing
- This is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which ST-segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(TIMI thrombus grade ≥3) are included. Patients are randomized to be treated with or without manual thrombus aspiration(TA) during primary percutaneous coronary intervention(PPCI) by a ratio of 1:1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years;
- STEMI patients undergoing primary PCI within 12 hours after the onset of symptoms;
- High thrombus burden after guidewire passes the lesion (TIMI thrombus grade ≥3);
- Informed consent must be voluntary;
You likely can't join if
- Haemodynamic instability or cardiogenic shock;
- After thrombolytic therapy;
- The predicted survival time is less than 6 months due to non-cardiac disease;
- History of coronary artery bypass grafting;
- Participate in other researches within 30 days;
- Preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy;
See the full eligibility criteria
- Age ≥ 18 years;
- STEMI patients undergoing primary PCI within 12 hours after the onset of symptoms;
- High thrombus burden after guidewire passes the lesion (TIMI thrombus grade ≥3);
- Informed consent must be voluntary;
- Haemodynamic instability or cardiogenic shock;
- After thrombolytic therapy;
- The predicted survival time is less than 6 months due to non-cardiac disease;
- History of coronary artery bypass grafting;
- Participate in other researches within 30 days;
- Preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy;
- Patients were considered unsuitable by other researchers.
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
- Foshan, Guangdong, China
- Guangzhou, Guangdong, China
- Huizhou, Guangdong, China
- Jiangmen, Guangdong, China
- Kaiping, Guangdong, China
- Maoming, Guangdong, China
- Shantou, Guangdong, China
- Shaoguan, Guangdong, China
- Shenzhen, Guangdong, China
- Taishan, Guangdong, China
- Xiongzhou, Guangdong, China
- Yangjiang, Guangdong, China
- Zhanjiang, Guangdong, China
- Zhaoqing, Guangdong, China
- Zhongshan, Guangdong, China
- Zhuhai, Guangdong, China
- Guilin, Guangxi, China
- Haikou, Hainan, China
- Wuhan, Hubei, China
+ 10 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China; Foshan, Guangdong, China; Guangzhou, Guangdong, China; Huizhou, Guangdong, China; Jiangmen, Guangdong, China; Kaiping, Guangdong, China and 24 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.